Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlight the need for biomarkers than can be measured early and in accessible samples such as plasma. However, despite extensive investigations, efforts have failed to yield biomarkers with adequate diagnostic accuracy and utility for CCA. We will address previous limitations in the discovery of CCA biomarker(s) by undertaking a biomarker program in the global epicenter of CCA, Khon Kaen province, Thailand, which has highest incidence of intrahepatic CCA in the world. A key factor in the success of this proposal is that, while the causative agent for CCA in the West remains obscure, the single most important risk factor for intrahepatic CCA in Thailand has long been established - infection with the liver fluke Opisthorchis viverrini (OV). As determined by the WHO's IARC, no stronger link between a human malignancy and a eukaryotic pathogen exists than between CCA and infection with OV. We will utilize this well-established link between a parasite infection and cancer for the discovery and verification of biomarkers for CCA in plasma. Using a quantitative proteomic approach, we propose to scan 30 frozen, resected liver tumor tissues from confirmed OV-induced CCA cases to assemble a suite of proteins (candidate biomarkers) proximal to the disease site. We will complement this analysis with a scan of CCA cell lines which, unlike the frozen liver sections, measure the expression of secreted/membrane proteins (the secretome). Potential biomarkers identified from these two sources will be verified in plasma samples paired with the 30 frozen, resected liver tissues from confirmed OV-induced CCA patients. The candidate biomarkers will then be verified in the plasma of OV- infected individuals at risk for CCA in a case control study from our NIAID-sponsored longitudinal study that traces cholangiocarcinogenesis from chronic O. viverrini infection to CCA. The use of this exceptional set of samples will enable us to address previous limitations to CCA biomarker discovery as follows. First, we can reliably measure risk for exposure by determining infection with OV. Second, the Khon Kaen study site has the highest incidence of CCA in the world, giving us access to large numbers of CCA samples. Third, using our NIAID-sponsored longitudinal study, we can trace pathogenesis along the entire continuum: from infection with OV to diagnosis with CCA. Fourth, we plan biomarker discovery in banked tissue proximal to the tumor (resected liver) followed by verification in plasma from these same CCA patients and then in """"""""at risk"""""""" patients in our cohort study. Hence, the overarching innovation of this proposal is that we will utilize a model of human carcinogenesis in which the major risk factor, as well as many of the intermediate stages on the pathway, to CCA have been well-defined.

Public Health Relevance

Cholangiocarcinoma (CCA) is a form of liver cancer with a devastatingly poor prognosis. In East Asia, unlike in the West, long term infection with a parasitic worm leads to CCA. Because of access to numerous cases of CCA in Thailand and nearby countries, and because it is feasible to monitor the development of CCA from the time of infection with the parasite, we propose a biomarker discovery program using CCA samples from liver fluke infected persons in Thailand. This could eventuate in tools for early diagnosis of CCA, which are not available at present, and thereby allow for treatment, not only in Asian populations but for people at risk of CCA in the US and other western countries.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA155297-03
Application #
8444662
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Rinaudo, Jo Ann S
Project Start
2011-04-15
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
3
Fiscal Year
2013
Total Cost
$490,037
Indirect Cost
$105,589
Name
George Washington University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
043990498
City
Washington
State
DC
Country
United States
Zip Code
20052
van Tong, Hoang; Brindley, Paul J; Meyer, Christian G et al. (2017) Parasite Infection, Carcinogenesis and Human Malignancy. EBioMedicine 15:12-23
Khoontawad, Jarinya; Pairojkul, Chawalit; Rucksaken, Rucksak et al. (2017) Differential Protein Expression Marks the Transition From Infection WithOpisthorchis viverrinito Cholangiocarcinoma. Mol Cell Proteomics 16:911-923
Saltykova, Irina V; Ogorodova, Ludmilla M; Ivanov, Vladimir V et al. (2017) Carbonyl stress phenomena during chronic infection with Opisthorchis felineus. Parasitol Int 66:453-457
Potriquet, Jeremy; Laohaviroj, Marut; Bethony, Jeffrey M et al. (2017) A modified FASP protocol for high-throughput preparation of protein samples for mass spectrometry. PLoS One 12:e0175967
Laohaviroj, Marut; Chamgramol, Yaovalux; Pairojkul, Chawalit et al. (2016) Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases. Asian Pac J Cancer Prev 17:201-5
Saltykova, Irina V; Petrov, Vjacheslav A; Logacheva, Maria D et al. (2016) Biliary Microbiota, Gallstone Disease and Infection with Opisthorchis felineus. PLoS Negl Trop Dis 10:e0004809
Gouveia, Maria João; Santos, Júlio; Brindley, Paul J et al. (2015) Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. Cancer Lett 359:226-32
Martin, John; Rosa, Bruce A; Ozersky, Philip et al. (2015) Helminth.net: expansions to Nematode.net and an introduction to Trematode.net. Nucleic Acids Res 43:D698-706
Brindley, Paul J; da Costa, José M Correia; Sripa, Banchob (2015) Why does infection with some helminths cause cancer? Trends Cancer 1:174-182
Chaiyadet, Sujittra; Smout, Michael; Johnson, Michael et al. (2015) Excretory/secretory products of the carcinogenic liver fluke are endocytosed by human cholangiocytes and drive cell proliferation and IL6 production. Int J Parasitol 45:773-81

Showing the most recent 10 out of 28 publications